Shire PLC (SHPG) Shares Gap Up to $203.44
Shire PLC (NASDAQ:SHPG)’s share price gapped up prior to trading on Tuesday . The stock had previously closed at $202.01, but opened at $203.44. Shire PLC shares last traded at $206.90, with a volume of 1,161,210 shares changing hands.
Several research firms recently commented on SHPG. Jefferies Group reiterated a “buy” rating and issued a $262.00 price objective on shares of Shire PLC in a research note on Tuesday. Sanford C. Bernstein restated an “outperform” rating and set a $222.00 target price on shares of Shire PLC in a research report on Thursday, June 9th. Royal Bank Of Canada restated an “outperform” rating on shares of Shire PLC in a research report on Wednesday, June 15th. BTIG Research restated a “buy” rating and set a $230.00 target price on shares of Shire PLC in a research report on Tuesday, July 12th. Finally, RBC Capital Markets restated an “outperform” rating on shares of Shire PLC in a research report on Wednesday, August 3rd. Four equities research analysts have rated the stock with a hold rating and twenty-four have assigned a buy rating to the company’s stock. Shire PLC currently has a consensus rating of “Buy” and a consensus price target of $230.67.
The firm has a 50 day moving average price of $195.71 and a 200-day moving average price of $183.68. The stock has a market capitalization of $61.52 billion, a P/E ratio of 42.93 and a beta of 1.11.
Shire PLC (NASDAQ:SHPG) last posted its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $3.38 earnings per share for the quarter, topping analysts’ consensus estimates of $3.03 by $0.35. Shire PLC had a net margin of 13.19% and a return on equity of 17.70%. The firm had revenue of $2.43 million for the quarter, compared to the consensus estimate of $2.28 billion. During the same period in the previous year, the firm posted $2.63 EPS. The business’s quarterly revenue was up 55.9% on a year-over-year basis. Equities research analysts predict that Shire PLC will post $12.93 EPS for the current year.
The firm also recently announced a dividend, which will be paid on Friday, October 7th. Stockholders of record on Friday, September 9th will be issued a $0.139 dividend. The ex-dividend date is Wednesday, September 7th. Shire PLC’s dividend payout ratio (DPR) is presently 15.63%.
Several hedge funds have recently bought and sold shares of the company. Renaissance Technologies LLC increased its position in shares of Shire PLC by 12.6% in the first quarter. Renaissance Technologies LLC now owns 313,212 shares of the biopharmaceutical company’s stock valued at $53,841,000 after buying an additional 35,100 shares during the last quarter. Bayesian Capital Management LP purchased a new position in shares of Shire PLC during the first quarter valued at approximately $224,000. Commerzbank Aktiengesellschaft FI purchased a new position in shares of Shire PLC during the second quarter valued at approximately $830,000. Assetmark Inc. increased its position in shares of Shire PLC by 5.8% in the second quarter. Assetmark Inc. now owns 2,927 shares of the biopharmaceutical company’s stock valued at $539,000 after buying an additional 160 shares during the last quarter. Finally, Pioneer Investment Management Inc. increased its position in shares of Shire PLC by 30.6% in the fourth quarter. Pioneer Investment Management Inc. now owns 15,699 shares of the biopharmaceutical company’s stock valued at $3,218,000 after buying an additional 3,680 shares during the last quarter. Hedge funds and other institutional investors own 24.61% of the company’s stock.
About Shire PLC
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.